JPRN-UMIN000002229已完成2 期
Photodynamic therapy with half dose verteporfin for central serous chorioretinopathy:Prospective intervention trial - Photodynamic therapy with half dose verteporfin for central serous chorioretinopathy
agoya University School of Medicine Department of Ophthalmology0 个研究点目标入组 10 人开始时间: 2009年7月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. drug allery to verteporfin 2. pregnant or expecting pregnancy 3. porphyria, or hypersensitivity to artificial illumination 4. macular diseases other than CSC 5. others (inappropriate case judged by investigator or subinvestigators)
研究者
相似试验
进行中（未招募）
1 期
A Phase 1 Trial of Verteporfin Photodynamic Therapy in Unresectable Pancreatic Carcinoma (VERTPAC-01 study) - VERTPAC-01EUCTR2006-004097-28-GBniversity College Hospitals NHS Foundation Trust/ University College London12
已完成
2 期
Photodynamic therapy with one third dose verteporfin for central serous chorioretinopathy:Prospective intervention trialCentral serous chorioretinopathyJPRN-UMIN000002405agoya University School of Medicine Department of Ophthalmology6
已完成
2 期
Photodynamic therapy with two third dose verteporfin for central serous chorioretinopathy:Prospective intervention trialCentral serous chorioretinopathyJPRN-UMIN000002770agoya University School of Medicine Department of Ophthalmology6
尚未招募
不适用
Verteporfin photodynamic therapy for central serous chorioretinopathyCentral serous chorioretinopathyJPRN-UMIN000020677Kansai Medical University30
已完成
不适用
Reduced fluence photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor antibody for age-related macular degeneration.Age-related macular degenerationJPRN-UMIN000004562Yamagata University Faculty of Medicine50